Cargando…

Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients

BACKGROUND: The European baseline series (EBS) of contact allergens is subject to change. An allergen is considered for inclusion when routine patch testing of patients with suspected contact dermatitis results in ≥0.5% prevalence rate. OBJECTIVES: We aimed to determine the frequency of sensitizatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Bizjak, Mojca, Adamič, Katja, Bajrovič, Nissera, Eržen, Renato, Jošt, Maja, Kopač, Peter, Košnik, Mitja, Lalek, Nika, Zidarn, Mihaela, Dinevski, Dejan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796124/
https://www.ncbi.nlm.nih.gov/pubmed/35736503
http://dx.doi.org/10.1111/cod.14178
_version_ 1784860412119875584
author Bizjak, Mojca
Adamič, Katja
Bajrovič, Nissera
Eržen, Renato
Jošt, Maja
Kopač, Peter
Košnik, Mitja
Lalek, Nika
Zidarn, Mihaela
Dinevski, Dejan
author_facet Bizjak, Mojca
Adamič, Katja
Bajrovič, Nissera
Eržen, Renato
Jošt, Maja
Kopač, Peter
Košnik, Mitja
Lalek, Nika
Zidarn, Mihaela
Dinevski, Dejan
author_sort Bizjak, Mojca
collection PubMed
description BACKGROUND: The European baseline series (EBS) of contact allergens is subject to change. An allergen is considered for inclusion when routine patch testing of patients with suspected contact dermatitis results in ≥0.5% prevalence rate. OBJECTIVES: We aimed to determine the frequency of sensitizations to 30 EBS allergens and 10 locally added allergens. Additionally, we assessed the strength and evolution of reactions to all tested allergens and co‐reactivity of additional allergens. METHODS: Patch testing with our baseline series of 40 allergens was done in 748 consecutive adults. Tests were applied to the upper back and removed by patients after 48 h. Readings were done on Day 3 (D3) and D6 or D7 (D6/7). Positive reactions fulfilled the criteria of at least one plus (+) reaction. A retrospective analysis was done. RESULTS: Eight allergens not listed in the EBS had ≥0.5% prevalence rate (i.e., cocamidopropyl betaine, thiomersal, disperse blue mix 106/124, 2‐bromo‐2‐nitropropane‐1,3‐diol, diazolidinyl urea, propylene glycol, Compositae mix II and dexamethasone‐21‐phosphate), and 16.6% of positive reactions would have been missed without D6/7 readings. CONCLUSION: We propose further studies to evaluate whether cocamidopropyl betaine, disperse blue mix 106/124, 2‐bromo‐2‐nitropropane‐1,3‐diol, diazolidinyl urea and Compositae mix II need to be added to the EBS.
format Online
Article
Text
id pubmed-9796124
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-97961242022-12-30 Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients Bizjak, Mojca Adamič, Katja Bajrovič, Nissera Eržen, Renato Jošt, Maja Kopač, Peter Košnik, Mitja Lalek, Nika Zidarn, Mihaela Dinevski, Dejan Contact Dermatitis Original Articles BACKGROUND: The European baseline series (EBS) of contact allergens is subject to change. An allergen is considered for inclusion when routine patch testing of patients with suspected contact dermatitis results in ≥0.5% prevalence rate. OBJECTIVES: We aimed to determine the frequency of sensitizations to 30 EBS allergens and 10 locally added allergens. Additionally, we assessed the strength and evolution of reactions to all tested allergens and co‐reactivity of additional allergens. METHODS: Patch testing with our baseline series of 40 allergens was done in 748 consecutive adults. Tests were applied to the upper back and removed by patients after 48 h. Readings were done on Day 3 (D3) and D6 or D7 (D6/7). Positive reactions fulfilled the criteria of at least one plus (+) reaction. A retrospective analysis was done. RESULTS: Eight allergens not listed in the EBS had ≥0.5% prevalence rate (i.e., cocamidopropyl betaine, thiomersal, disperse blue mix 106/124, 2‐bromo‐2‐nitropropane‐1,3‐diol, diazolidinyl urea, propylene glycol, Compositae mix II and dexamethasone‐21‐phosphate), and 16.6% of positive reactions would have been missed without D6/7 readings. CONCLUSION: We propose further studies to evaluate whether cocamidopropyl betaine, disperse blue mix 106/124, 2‐bromo‐2‐nitropropane‐1,3‐diol, diazolidinyl urea and Compositae mix II need to be added to the EBS. Blackwell Publishing Ltd 2022-07-08 2022-11 /pmc/articles/PMC9796124/ /pubmed/35736503 http://dx.doi.org/10.1111/cod.14178 Text en © 2022 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Bizjak, Mojca
Adamič, Katja
Bajrovič, Nissera
Eržen, Renato
Jošt, Maja
Kopač, Peter
Košnik, Mitja
Lalek, Nika
Zidarn, Mihaela
Dinevski, Dejan
Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients
title Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients
title_full Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients
title_fullStr Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients
title_full_unstemmed Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients
title_short Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients
title_sort patch testing with the european baseline series and 10 added allergens: single‐centre study of 748 patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796124/
https://www.ncbi.nlm.nih.gov/pubmed/35736503
http://dx.doi.org/10.1111/cod.14178
work_keys_str_mv AT bizjakmojca patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients
AT adamickatja patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients
AT bajrovicnissera patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients
AT erzenrenato patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients
AT jostmaja patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients
AT kopacpeter patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients
AT kosnikmitja patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients
AT laleknika patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients
AT zidarnmihaela patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients
AT dinevskidejan patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients